ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Editorial: Ambiance Through Exclusion

May 20, 1994

OCC Has Answers Ready Or Most Questions Asked

March 21, 1980

In Brief: Phil Web, Former NCI Contracts Official, Dies; Minimal Breast Cancer Workshop Set

February 15, 1980

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Organ Systems Program Progress, Momentum Threatened During transition, Karr Contends

December 9, 1988

DCT Advisors Approve Recompetition Of Drug Discovery Groups

June 23, 1995